Toll-like receptors (TLRs) play a critical role in the detection of invading pathogens within the body and the subsequent immune response. Individual TLRs recognize distinct microbial components. The TLRs are a type 1 transmembrane receptor that possess an extracellular leucine-rich repeat domain and cytoplasmic domain homologous with that of the interleukin 1 receptor (IL-1R) family. Upon stimulation, TLR recruits the IL-1R-associated kinase (IRAK) via the adapter MyD88, ultimately leading to the activation of nuclear factor-κB. Cytokine production in response to all TLR ligands is completely abolished in MyD88-deficient cells, indicating that MyD88 is an essential signalling molecule shared among members of the IL-1R/Toll family. However, several novel adaptor molecules have recently been identified. Evidence is now accumulating showing that differential utilization of these adaptors may activate overlapping as well as distinct signalling pathways, and ultimately give rise to distinct biological effects exerted by individual TLR family members.
Introduction
The immune response in vertebrates is broadly categorized into innate and acquired immunity. Innate immunity is the first line of defence against invading pathogens. The main players in innate immunity are phagocytes, such as neutrophils, macrophages and dendritic cells. These phagocytes destroy pathogens by engulfing and digesting them. They also discriminate between pathogens and self via the family of Toll-like receptors (TLRs). TLRs recognize conserved molecular motifs found in micro-organisms, but which are rare or absent in vertebrates. Engagement of the TLRs triggers anti-microbial responses and cytokine production. More importantly, induction of acquired immunity depends entirely on innate immunity. Dendritic cells, which are recruited as antigen-presenting cells, process pathogenderived antigens and present them on the cell surface, together with major histocompatibility antigens. Thereafter, these cells migrate from the infected tissue to the regional lymph node, where they present antigen to naïve T-cells. However, antigen
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presentation alone does not activate T-cells, but rather results in the induction of anergy, i.e. immune unresponsiveness. Efficient T-cell activation requires, in addition, the activation of dendritic cells, which involves the induction of costimulatory molecules as well as cytokine production. This dendritic cell activation is initiated by the stimulation of TLRs expressed on the surface of these cells. Thus TLRs play a crucial role in the induction of acquired immunity, as well as of innate immunity [1] [2] [3] .
Mammalian TLRs
There are ten members of the TLR family identified to date. TLRs comprise a subfamily within the larger superfamily of interleukin (IL) receptors, based on similarity within their cytoplasmic regions. In contrast, the extracellular regions are quite distinct: whereas the extracellular region of the IL type-1 receptors (IL-1Rs) possesses three immunoglobulinlike domains, that of TLRs is characterized by the presence of leucine-rich repeats.
Stimulation of IL-1R or TLR by their respective ligands causes the adapter protein MyD88 to be recruited to the receptor complex, which in turn promotes its association with the IL-1R-associated kinase (IRAK) via an interaction between the respective death domains of each molecule. This is followed by the autophosphorylation of IRAK, which dissociates from the receptor complex and interacts with TRAF-6 (tumour-necrosis-factor-receptor-associated The responses to all ligands, except for dsRNA, are dependent on MyD88, as assayed by inflammatory cytokine production.
MyD88 does not appear to be involved in dsRNA-dependent TLR3 signalling. X, unknown.
factor-6). From TRAF-6, two signalling pathways diverge; one ultimately leads to nuclear factor-κB (NF-κB) activation, and the other to mitogen-activated protein (MAP) kinase activation. Originally, the Drosophila Toll protein was shown to be essential for the anti-fungal response in this species. This suggested that mammalian TLRs may also participate in innate immunity. Indeed, TLRs were subsequently found to be essential for microbial recognition ( Figure 1 ). Below, we describe the specific recognition of conserved pathogen motifs by each mammalian TLR. TLR4 recognizes lipopolysaccharide (LPS), an integral component of the outer membranes of Gram-negative bacteria, and a causative agent of endotoxin shock [4, 5] . Recognition of LPS requires not only TLR4, but also a TLR4-accessory molecule, MD-2 [6] .
TLR2 is involved in the response to a variety of bacterial components. They include peptidoglycan, lipoproteins/ lipopeptides, glycosyl-phosphatidylinositol anchors from Trypanosoma cruzi, and zymosan, a component of yeast cell walls [7] [8] [9] [10] [11] [12] [13] . These TLR2 ligands are probably recognized by a heterodimer formed between TLR2 and another TLR family member [14] [15] [16] . For example, lipoproteins and lipopeptides both possess an N-terminal lipid moiety that is essential for their immunostimulatory activities. Figure 2 depicts the structural differences between MALP-2 (2-kDa macrophage-activating lipopeptide), a mycoplasma-derived synthetic lipopeptide, and PAM3CSK4, a synthetic bacterial lipopeptide. PAM3CSK4 possesses a triacylated cysteine residue at the N-terminus, whereas the cysteine residue in MALP-2 is diacylated. Our experiments with TLR1, TLR2 and TLR6 knock-out mice demonstrate that the mycoplasmal diacylated lipopeptide MALP-2 is recognized by heterodimers formed between TLR2 and TLR6, whereas the bacterial lipopeptide PAM3CSK4 is probably recognized by a heterodimer formed between TLR2 and TLR1 [15, 16] .
TLR9 recognizes unmethylated 2 -deoxyribo(cytidinephosphate-guanosine) (CpG) DNA motifs that are more commonly found in bacterial and viral genomes, and not in vertebrate genomes [17] . Where these sequences do occur in vertebrate genomes, they are typically methylated. Unmethylated bacterial and viral DNA, as well as synthetic unmethylated CpG dinucleotide ('CpG ODN'), have demonstrated potent immunostimulatory activity. However, this immunostimulation was defective in TLR9-deficient mice: unmethylated CpG DNA did not induce inflammatory cytokine production in macrophages, proliferation of B-cells or maturation of dendritic cells. CpG DNA-induced activation of several signalling molecules, such as NF-κB, c-Jun N-terminal kinase ('JNK') and IRAK, was also severely impaired in TLR9-deficient mice. TLR5 recognizes flagellin, a 55 kDa monomer obtained from bacterial flagella, a polymeric rod-like appendage extending from the outer membrane of Gram-negative bacteria that propels the organism through its aqueous environment [18] . Flagellin is also a potent pro-inflammatory factor.
TLR3 recognizes double-stranded (ds) RNA [19] . Viral replication within infected cells results in the generation of dsRNA, suggesting a role for TLR3 in viral recognition.
TLR7 recognizes the pharmaceutical compounds Imiquimod (also known as Aldara, R-837, S-26308) and Resiquimod (also known as R-848 or S-28463) [20] . These are low-molecular-mass compounds of the imidazoquinoline family that have demonstrated potent antiviral and antitumour properties in animal models. The activity of Imiquimod is mediated predominantly by the induction of cytokines, including interferon (IFN)-α and IL-12. Topical Imiquimod therapy is now approved for the treatment of external genital and peri-anal warts caused by papilloma virus infection.
Role of MyD88 in the response to microbial components
MyD88 was originally isolated as a myeloid differentiation primary response gene that is rapidly induced upon IL-6-stimulated differentiation of M1 myeloleukaemic cells into macrophages [21] . The C-terminal domain of MyD88 is highly homologous with the cytoplasmic regions of the IL-1 receptor family [22] . However, unlike the IL-1 receptor family, MyD88 does not contain a transmembrane portion, and contains a death domain in its N-terminus. Subsequently, MyD88 was cloned as an adapter molecule that functions to recruit IRAK to the IL-1R complex after IL-1 stimulation, an event that leads to the activation of NF-κB [23, 24] .
MyD88-deficient mice have been generated and found to be completely defective in their responses to IL-1 and the IL-1-related cytokine IL-18 [25] . The response to LPS was also abolished in MyD88 knock-out mice [26] . Furthermore, MyD88-deficient macrophages were completely unresponsive to other immunostimulatory bacterial components, including peptidoglycan, lipoproteins, CpG DNA and imidazoquinolines, demonstrating an essential role for MyD88 in the responses to most, or all, pathogen-derived immunostimulatory molecules. However, in the case of TLR3 signalling, the role of MyD88 is complex, because some responses to poly(dI-dC) are not impaired in MyD88-deficient mice [19] .
MyD88-dependent and -independent pathways of LPS signalling
MyD88-deficient mice failed to respond to LPS and other microbial cell-wall components, such as peptidoglycan and lipopeptides, or to either IL-1 or IL-18. However, there was a difference in the signalling pathways triggered by LPS and by these other stimuli. Activation of NF-κB and MAP kinases in response to mycoplasmal lipopeptide was completely abolished in TLR2-deficient or MyD88-deficient macrophages [21] . However, LPS activation of MAP kinases and NF-κB remained intact in MyD88-deficient macrophages, although activation was delayed compared with the responses in wild-type mice. This indicates that the LPS response may be mediated by both MyD88-dependent and -independent pathways, each of which lead to the activation of MAP kinases and NF-κB.
In an attempt to characterize the MyD88-independent pathway, we searched for genes induced by LPS in MyD88-deficient mice. We generated a cDNA library from MyD88-deficient macrophages before and after LPS stimulation and performed subtractive suppression hybridization [27] . This screen identified several genes induced in LPS-stimulated MyD88-deficient macrophages. Most of these were so-called IFN-inducible genes, such as IP-10 (IFN-inducible protein-10; a CXC chemokine), GARG16 (glucocorticoid attenuated response gene 16) and IRG-1 ('IFN-regulated gene 1'). Consistent with the apparent lack of any MyD88-independent pathway of TLR2 signalling, wild-type macrophages did not induce IP-10 mRNA in response to mycoplasmal lipopeptide. IFN-inducible genes are typically induced by type 1 IFNs. Analyses with IFN-α/β receptor knock-out mice and signal transducer of transcription 1 ('STAT1') knock-out mice showed that IP-10 induction is secondary to IFN-β induction in response to LPS [28, 29] . In contrast, GARG16 was induced independently of MyD88 and IFN-β. Previous studies showed that IFNinducible genes, including IP-10, are regulated by IFN regulatory factor 3 (IRF-3) [30] . Following viral infection, treatment with dsRNA or LPS stimulation, IRF-3 undergoes phosphorylation and translocates from the cytoplasm to the nucleus, resulting in the transcriptional activation of IFN-inducible genes. As expected, activation of IRF-3 and its binding to IFN-stimulated response elements were unaffected in MyD88-deficient cells [27] . Figure 2 summarizes the differences in the signalling pathways and gene expression induced by LPS compared with mycoplasmal lipoprotein.
In addition to the induction of IFN-inducible genes, the MyD88-independent pathway was also shown to be involved in the LPS-mediated maturation of dendritic cells. This maturation is accompanied by the induction of costimulatory molecules and production of inflammatory cytokines. LPS stimulation of MyD88-deficient bonemarrow-derived dendritic cells resulted in augmented surface expression of co-stimulatory molecules such as CD40, CD80 and CD86, and activation of T-cell proliferation. In contrast, TLR4-deficient dendritic cells failed to maturate in response to LPS, indicating that LPS-induced dendritic cell maturation can proceed without MyD88 [31] . Further studies showed that activation of either the MyD88-dependent or MyD88-independent pathway is sufficient for induction of co-stimulatory molecules. However, MyD88-independent induction of co-stimulatory molecules is secondary to IFN-β induction, similar to the case of IFN-inducible genes (Figure 2 ).
Identification of other adaptor molecules involved in TLR signalling
Recently, a novel protein containing a Toll/IL-1 receptor (TIR) domain was independently identified by two groups. Medzhitov and co-workers named this protein the TIR domain-containing adaptor protein (TIRAP) [32] . They showed that TIRAP overexpression led to activation of NF-κB in HEK-293 cells, and that TIRAP associated with TLR-4, but not with other TLR family members. In addition, they showed that overexpression of a dominant-negative form of TIRAP inhibited LPS-induced NF-κB activation or dendritic cell maturation, but did not affect similar CpG DNA-induced responses. O'Neill and co-workers named the same molecule MyD88-adapter-like (Mal) [33] . They showed that Mal activates NF-κB via IRAK-2, but not IRAK-1, by forming heterodimers with MyD88.
It was initially expected that TIRAP/Mal might participate in MyD88-independent NF-κB activation [28, 32, 33] . However, studies with TIRAP-deficient mice have revealed that TIRAP/Mal is not involved in the MyD88-independent pathway, but rather acts as an adapter in the MyD88-dependent signalling pathways initiated via TLR2 and TLR4 [34, 35] . These studies suggest that several TIR-containing adapter molecules may be involved in TLR-mediated signalling pathways, and that their differential utilization may provide specificity in TLR signalling. These studies show further that the MyD88-independent signalling pathway is mediated by a molecule other than TIRAP.
To clarify further the TLR signalling pathways, we searched for adapter molecules in addition to MyD88 and TIRAP that contain TIR domains. Search of gene databases identified a novel adapter molecule we named TRIF (TIR domain-containing adapter inducing IFNs) [36] . The mouse TRIF cDNA encodes a polypeptide of 712 amino acids, and the TRIF messenger is expressed ubiquitously in all tissues, with particularly strong expression in the liver. We examined the effect of TRIF overexpression on TLR signalling. In this experiment, we used two types of reporter plasmids: an NF-κB-responsive ELAM1 ('endothelial leukocyte adhesion molecule 1') promoter-luciferase gene and an IFN-β promoter-luciferase gene. Overexpression of TRIF activated MyD88 is essential for inflammatory cytokine production in response to all TLR ligands, except for the TLR3 ligand. TIRAP/Mal is essential for TLR2-dependent and TLR4-dependent inflammatory cytokine production, but is not involved in the MyD88-independent pathway of TLR4 signalling. TRIF may be involved in TLR3 signalling. Trif may also be involved in the MyD88-independent pathway of TLR4 signalling as well as IFN induction via other TLRs, such as TLR7 and TLR9.
both promoters in the absence of TLR ligand. However, TRIF overexpression preferentially activates the IFN-β promoter.
A dominant-negative form of TRIF, but not of MyD88 or TIRAP, blocked the poly(dI-dC)-mediated TLR3 response, indicating a specific role of this novel adaptor in TLR3 signalling ( Figure 3 ). The dominant-negative form of TRIF also blocked signalling by other TLR family members, which indicates further a role for TRIF in the MyD88-dependent pathway. Further analyses, including generation of TRIFknockout mice, will be required to understand more precisely the role of Trif in TLR signalling (Figure 3 ).
Conclusion
Individual TLRs activate different signalling pathways and exert distinct biological effects. Our experiments with MyD88 knock-out mice have demonstrated the existence of both MyD88-dependent and MyD88-independent pathways mediating TLR4 signalling. Recently, another adaptor molecule named TIRAP/Mal was suggested to be responsible for the MyD88-independent pathway of TLR4 signalling. However, studies on mice which had had their TIRAP/Mal gene deleted provided the unexpected finding that TIRAP/Mal is not involved in the MyD88-independent pathway, but rather is essential for the MyD88-dependent pathway utilized by TLR2 and TLR4, but not other TLRs. We have recently identified a novel adapter named TRIF, which specifically activates IRF-3 and induces the IFN-β promoter, indicating that TRIF may be involved in MyD88-independent pathways in TLR signalling. Of course, we must await the generation of TRIF knock-out mice to verify this speculation. The TRIF-dependent pathway may also be linked to the responses to viral infection. The elucidation of the TRIF pathway may provide new insights into the molecular mechanisms of type 1 IFN induction during viral infection.
